NEW YORK (TheStreet) -- Halozyme plunged Friday morning after the biopharmaceutical company announced that it would temporarily suspend enrollment in an ongoing Phase 2 trial of its PEGPH20 treatment of patients with pancreatic cancer.
Halozyme Therapeutics, Inc. (Nasdaq: HALO)
announced that as a result of a recommendation received yesterday from an independent Data Monitoring Committee (DMC), it is temporarily halting patient enrollment and dosing of PEGPH20 in an...
Halozyme Therapeutics (NASDAQ: HALO) fell 23.73% to $8.84 in pre-market trading after the company announced the temporary halt of Phase 2 trial enrollment.
Ocean Power Technologies (NASDAQ: OPTT) dipped 17.89% to $3.12 in the pre-market session...
SOUTH SAN FRANCISCO (dpa-AFX) - Halozyme Therapeutics Inc (HALO) said
Friday the European Commission has approved Roche's (RHHBY) new subcutaneous
formulation of MabThera (rituximab) for the treatment of patients with
follicular lymphoma and...
WASHINGTON (dpa-AFX) - The FDA has approved Actavis plc's (ACT)
Metronidazole 1.3% Vaginal Gel, an antibiotic, for the treatment of bacterial
vaginosis. Actavis acquired the rights to Metronidazole 1.3% from Valeant
Halozyme Therapeutics (HALO)
Q4 2013 Earnings Call
February 27, 2014 4:30 pm ET
Helen I. Torley - Chief Executive Officer, President and Director
David A. Ramsay - Chief Financial Officer and Vice...
Oops! Unable to complete your request. Please refresh your browser.
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article.